Company intelligence / Profile preview
Menlo Therapeutics
Redwood City, California, United Statesmenlotherapeutics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The company's lead program, serlopitant (VPD-737), demonstrated positive results in Phase 2 clinical trials for chronic pruritus and prurigo nodularis, meeting primary and secondary endpoints in over 380 patients. Preparation for Phase 3 trials for prurigo nodularis and further development in related indications were underway as of 2018.[2][4][6][10]
- Therapeutic areas
- DermatologyPulmonology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Merck (licensor of serlopitant)Velocity Pharmaceutical Holdings (founder/investor)Remeditex Ventures (investor)Presidio PartnersVivo CapitalvenBio Global Strategic Fund IIF-PrimeNovo Holdings A/SRock Springs CapitalAisling CapitalBay City Capital
Beyond the preview
Go deeper on Menlo Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Menlo Therapeutics.